An artificial intelligence-powered communication app helps people with amyotrophic lateral sclerosis (ALS) and other conditions that affect speech keep…
Articles by Michela Luciano, PhD
Otsuka Pharmaceutical’s experimental therapy ulefnersen improved a combined measure of function and survival compared with a placebo in people…
A newer set of diagnostic criteria for amyotrophic lateral sclerosis (ALS) was significantly more sensitive at identifying people with…
Stem cell therapies are generally safe and well tolerated in people with amyotrophic lateral sclerosis (ALS), and preliminary evidence…
Neurosense Therapeutics plans to seek Health Canada approval by the end of the year for PrimeC, its experimental oral…
People whose jobs expose them to pesticides may be more likely to develop amyotrophic lateral sclerosis (ALS) than workers…
Editor’s note: This story includes discussion of suicide. If you or someone you know needs help, the national suicide and…
An experimental brain-computer interface that helped a man with amyotrophic lateral sclerosis (ALS) communicate again has earned a neuroscientist at…
The anticipated availability and subsequent approval in Canada of the first gene-targeted therapy for certain people with amyotrophic lateral…
A self-balancing, hands-free robotic exoskeleton designed for people with severe gait impairment was safe and well tolerated …